Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With Confirmed Small Fiber Neuropathy That is Idiopathic or Associated With Diabetes Mellitus

NCT03339336 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03339336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03339336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With Confirmed Small Fiber Neuropathy That is Idiopathic or Associated With Diabetes Mellitus
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2018
Completion date
April 12, 2021
Enrollment
265 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, small fiber neuropathy